B K Shanthaveerappa

Title: B K Shanthaveerappa: Innovator in HIF-1 Inhibition

Introduction: B K Shanthaveerappa is a notable inventor based in Taejeon-si, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of compounds that inhibit HIF-1 activity. His work has implications for cancer treatment and other medical conditions.

Latest Patents: B K Shanthaveerappa holds 1 patent for his invention titled "Compounds that inhibit HIF-1 activity, the method for preparation thereof and the pharmaceutical composition containing them as an effective component." This patent discloses an HIF-1 inhibitor that demonstrates anticancer activity by inhibiting HIF-1, a transcription factor crucial for cancer growth and metastasis. The invention is particularly relevant for treating various cancers, including liver, stomach, and breast cancer. Additionally, the compound is beneficial in addressing diabetic retinopathy and arthritis, conditions exacerbated by HIF-1-mediated VEGF expression.

Career Highlights: B K Shanthaveerappa is affiliated with the Korea Research Institute of Bioscience and Biotechnology. His research focuses on innovative solutions in the medical field, particularly in developing therapeutic agents that target critical pathways in cancer and other diseases.

Collaborations: He has collaborated with notable colleagues, including Jin Hwan Kim and Kyeong Seok Lee, contributing to advancements in their shared field of research.

Conclusion: B K Shanthaveerappa's work in HIF-1 inhibition represents a significant advancement in the fight against cancer and other related diseases. His innovative approach and dedication to research continue to pave the way for future breakthroughs in biotechnology.